ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2011
Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.British journal of cancer · 2017Trial
- Expression profile of interleukin-6, 4-hydroxy-2-nonenal, and hypoxia-inducible factor 1-α in women with breast cancer and their association with clinicopathological parameters.Contemporary oncology (Poznan, Poland) · 2023Article
- Immunity and Breast Cancer: Focus on Eosinophils.Biomedicines · 2021Review
- PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.Journal of clinical laboratory analysis · 2021Article
- Osteonecrosis of the Jaw Beyond Bisphosphonates: Are There Any Unknown Local Risk Factors?Clinical, cosmetic and investigational dentistry · 2021Article
- Volatile Anesthetics Regulate Anti-Cancer Relevant Signaling.Frontiers in oncology · 2021Review
- Research Trends and Regulation of CCL5 in Prostate Cancer.OncoTargets and therapy · 2021Review
- Chemokines and chemokine receptors: A new strategy for breast cancer therapy.Cancer medicine · 2020Review
- Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study.Scientific reports · 2020Article
- Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.International journal of molecular sciences · 2018Review
- Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment.Oncology letters · 2016Article
- High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system.Biosensors & bioelectronics · 2015Article
- Article
- Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype.Cancer research and treatment · 2013Article
- Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.Breast cancer research and treatment · 2013Article
- Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.Cellular and molecular life sciences : CMLS · 2012Review
- Photonic crystal enhanced fluorescence for early breast cancer biomarker detection.Journal of biophotonics · 2012Review
- Exposure to 60% oxygen promotes migration and upregulates angiogenesis factor secretion in breast cancer cells.Medical gas researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCurrent biomarkers for breast cancer have little potential for detection. We determined whether breast cancer subtypes influence circulating protein biomarkers.
methodsA sandwich ELISA microarray platform was used to evaluate 23 candidate biomarkers in plasma samples that were obtained from subjects with either benign breast disease or invasive breast cancer. All plasma samples were collected at the time of biopsy, after a referral due to a suspicious screen (e.g., mammography). Cancer samples were evaluated on the basis of breast cancer subtypes, as defined by the HER2 and estrogen receptor statuses.
resultsTen proteins were statistically altered in at least one breast cancer subtype, including four epidermal growth factor receptor ligands, two matrix metalloproteases, two cytokines, and two angiogenic factors. Only one cytokine, RANTES, was significantly increased (P < 0.01 for each analysis) in all four subtypes, with areas under the curve (AUC) for receiver operating characteristic values that ranged from 0.76 to 0.82, depending on cancer subtype. The best AUC values were observed for analyses that combined data from multiple biomarkers, with values ranging from 0.70 to 0.99, depending on the cancer subtype. Although the results for RANTES are consistent with previous publications, the multi-assay results need to be validated in independent sample sets.
conclusionsDifferent breast cancer subtypes produce distinct biomarker profiles, and circulating protein biomarkers have potential to differentiate between true- and false-positive screens for breast cancer. IMPACT: Subtype-specific biomarker panels may be useful for detecting breast cancer or as an adjunct assay to improve the accuracy of current screening methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.